Background
Results
MACC1 SNPs and Met variants in primary colorectal tumors
MACC1 SNPs have no impact on MACC1 expression
MACC1 SNPs do not affect motility and proliferation of colorectal cancer cells
MACC1 SNPs and association with metastasis or clinicopathological parameters
rs4721888 (L31V) | ||||||
---|---|---|---|---|---|---|
Parameters
|
Leu/Leu (ctc/ctc) (%)
|
Leu/Val (ctc/gtc) (%)
|
P-value
|
OR
|
95% CI
| |
All tumors, n = 154 | 134 (87%) | 20 (13%) | ||||
Metachronous metastasis,n = 29 | 27 (93%) | 2 (7%) | 0.28 | 0.44 | 0.10 - 2.02 | |
Gender male, n = 79 | 68 (86%) | 11 (14%) | 0.72 | 1.19 | 0.46 - 3.05 | |
Age > 66.32 years (median),n = 77 | 67 (87%) | 10 (13%) | 1.00 | 1.00 | 0.39 – 2.56 | |
pT3 and pT4, n = 118 | 102 (86%) | 16 (14%) | 0.70 | 1.26 | 0.39 - 4.03 | |
N1 to N3, n = 53 | 43 (81%) | 10 (19%) | 0.12 | 2.12 | 0.82 - 5.47 | |
UICC stage I, n = 26 | 24 (92%) | 2 (8%) | 0.38 | 0.51 | 0.11 - 2.34 | |
UICC stage II, n = 74 | 66 (89%) | 8 (11%) | 0.44 | 0.69 | 0.26 - 1.79 | |
UICC stage III, n = 54 | 44 (81%) | 10 (19%) | 0.13 | 2.05 | 0.79 - 5.28 | |
rs975263 (S515L)
| ||||||
Parameters
|
Ser/Ser (tcg/tcg) (%)
|
Ser/Leu (tcg/ttg) (%)
|
P-value
|
OR
|
95% CI
| |
All tumors, n = 154 | 80 (52%) | 74 (48%) | ||||
Metachronous metastasis,n = 29 | 12 (41%) | 17 (59%) | 0.21 | 1.69 | 0.75 – 3.83 | |
Gender male, n = 79 | 40 (51%) | 39 (49%) | 0.74 | 1.11 | 0.59 - 2.10 | |
Age > 66.32 years (median),n = 77 | 40 (52%) | 37 (48%) | 1.00 | 1.00 | 0.53 – 1.88 | |
pT3 and pT4, n = 118 | 63 (53%) | 55 (47%) | 0.52 | 0.78 | 0.37 - 1.65 | |
N1 to N3, n = 53 | 26 (49%) | 27 (51%) | 0.60 | 1.19 | 0.61 - 2.32 | |
UICC stage I, n = 26 | 14 (54%) | 12 (46%) | 0.83 | 0.91 | 0.39 - 2.13 | |
UICC stage II, n = 74 | 39 (53%) | 35 (47%) | 0.86 | 0.94 | 0.50 - 1.78 | |
UICC stage III, n = 54 | 27 (50%) | 27 (50%) | 0.72 | 1.13 | 0.58 - 2.19 | |
rs3735615 (R804T)
|
without R804T compared to with R804T
| |||||
Parameters
|
Arg/Arg (aga/aga) (%)
|
Arg/Thr (aga/aca) (%)
|
Thr/Thr (aca/aca) (%)
|
P-value
|
OR
|
95% CI
|
All tumors, n = 154 | 25 (16%) | 74 (48%) | 55 (36%) | |||
Metachronous metastasis,n = 29 | 5 (17%) | 15 (52%) | 9 (31%) | 0.95 | 0.96 | 0.33 - 2.80 |
Gender male, n = 79 | 11 (14%) | 37 (47%) | 31 (39%) | 0.43 | 1.42 | 0.60 - 3.36 |
Age > 66.32 years (median),n = 77 | 12 (16%) | 39 (51%) | 26 (34%) | 0.83 | 1.10 | 0.47 - 2.59 |
pT3 and pT4, n = 118 | 21 (18%) | 53 (45%) | 44 (37%) | 0.34 | 0.58 | 0.18 - 1.81 |
N1 to N3, n = 53 | 9 (17%) | 27 (51%) | 17 (32%) | 0.86 | 0.92 | 0.38 - 2.25 |
UICC stage I, n = 26 | 4 (15%) | 14 (54%) | 8 (31%) | 0.90 | 1.08 | 0.34 - 3.46 |
UICC stage II, n = 74 | 12 (16%) | 32 (43%) | 30 (41%) | 1.00 | 1.00 | 0.43 - 2.36 |
UICC stage III, n = 54 | 9 (17%) | 28 (52%) | 17 (32%) | 0.91 | 0.95 | 0.39 - 2.33 |
MACC1 SNPs and association with overall survival (OS) and metastasis-free survival (MFS) in all colorectal cancer patients
Younger colon cancer patients of early stages with a genotype 515 SL have a reduced MFS
Discussion
Conclusion
Methods
Patients
Characteristics | n (%) |
---|---|
Ethnicity | |
European | 154 (100%) |
Gender | |
Male | 79 (51%) |
Female | 75 (49%) |
Age at diagnosis (years) | |
Median ± SD: 66.32 ±10.44 | |
< 60 | 40 (26%) |
60-70 | 57 (37%) |
> 70 | 57 (37%) |
Localisation | |
Colon | 105 (68%) |
Rectum | 49 (32%) |
Metachronous metastasis | |
With | 29 (19%) |
Without | 125 (81%) |
UICC stage | |
I | 26 (17%) |
II | 74 (48%) |
III | 54 (35%) |
pT status | |
pT1 + 2 | 36 (23%) |
pT3 + 4 | 118 (77%) |
pN status | |
Negative | 101 (66%) |
Positive | 53 (34%) |
Microdissection and isolation of DNA and RNA
Polymerase chain reaction (PCR) and sequencing
Gene | Primer/Probe | Sequence 5’-3’ |
---|---|---|
MACC1, exon 4 | Forward primer | atctagtcgagtatcctaccag |
Reverse primer | cagaggtagaccttcaacaattat | |
MACC1, exon 5.1 | Forward primer | cttgattgtaactcacagtgcc |
Reverse primer | gaggttgcctaacatgatttcc | |
MACC1, exon 5.2 | Forward primer | gaattccaagaggtgtctctaag |
Reverse primer | cttcacctgcttccaactgc | |
MACC1, exon 5.3 | Forward primer | ggacacaattatatgccaggac |
Reverse primer | gcagtgtacaagtccaatcttac | |
MACC1, exon 5.4 | Forward primer | ggacacaattatatgccaggac |
Reverse primer | gcagtgtacaagtccaatcttac | |
MACC1, exon 5.5 | Forward primer | gcagtgctaagacaaagcaag |
Reverse primer | catttctcctctcacatggttcag | |
MACC1, exon 6 | Forward primer | ctctggcttagttatgtctactg |
Reverse primer | gtgaatccgtgaatgtggtatg | |
MACC1, exon 7 | Forward primer | gtccatgtgtaattggtattccg |
Reverse primer | tctgagattctttctttcctacac | |
Met, exon 14 | Forward primer | gtcgattcttgtgtgctgtctt |
Reverse primer | cagaggtaaatacttcctttagg | |
Met, exon 15 | Forward primer | gctaccactgcttccattcttaaggac |
Reverse primer | ttgcttccatgcacaagggcaaatcc | |
Met, exon 16 | Forward primer | gcttatatccttgggtgaaatgtgttgcatc |
Reverse primer | atgagggctctgagggatcatttcag | |
Met, exon 17 | Forward primer | aaccctcaggacaagatgctaa |
Reverse primer | ggtgcatttgaatgatgctaacat | |
Met, exon 18 | Forward primer | aggcttgagccattaagaccaa |
Reverse primer | ccagggcttacacatcgattta | |
Met, exon 19 | Forward primer | gaggccagatgaaatacttcct |
Reverse primer | atgaagaaaactggaattggtggt | |
MACC1, SNP L31V | Forward primer | gaagctggaaaagtctcaaaaagtt |
Reverse primer | aactttttgagacttttccagcttc | |
MACC1, SNP S515L | Forward primer | taaaaagactcttgaatctgccagg |
Reverse primer | cctggcagattcaagagtcttttta | |
MACC1, SNP R804T | Forward primer | gaaataactacacagatgtgttaca |
Reverse primer | tgtaacacatctgtgtagttatttc | |
MACC1, qRT-PCR | Forward primer | ttcttttgattcctccggtga |
Reverse primer | actctgatgggcatgtgctg | |
FITC-probe | gcagacttcctcaagaaattctggaagatcta-FITC | |
LCRed640 | LCRed640-agtgtttcagaacttctggacattttagacga |